Gyre Therapeutics, Inc. (GYRE)

From the record

Gyre Therapeutics, Inc.'s filings since 2017 show 8 warning events of 2 kinds: a notice about its exchange listing (8-K item 3.01, 7 times, the latest 2024-07-05); an auditor change (8-K item 4.01, the latest 2023-11-02) (its current reports).

From the record

Gyre Therapeutics, Inc.'s 8 filed years say what it did: revenue went from $1 million in fiscal 2017 to $117 million in fiscal 2025, up 80.9% a year; it rose in 4 of 7 years; the deepest fall was 99% from fiscal 2017 to fiscal 2018; net income was positive in 3 of 9 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Gyre Therapeutics, Inc.'s diluted share count grew about 10.9% a year, and dividends and buybacks returned about 0% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 18 sales (2 under scheduled 10b5-1 plans) and 0 purchases of their own stock on the open market in the year to 2026-09-30 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Gyre Therapeutics, Inc. earned about 9 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 67 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 36 cents per dollar of assets, and net share issuance: its share count grew 0.9% over the year (the filed statements).

From the record

Gyre Therapeutics, Inc.'s standing among 315 graded names in its industry family: revenue of $117 million in fiscal 2025 ranks in the top 33% by size; a net margin of 8.5% ranks in the top 18%; revenue growth of 4.5% a year over the last 3 filed years ranks in the bottom 46% (its annual reports).

From the record

Gyre Therapeutics, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Luo, Ying (Chief Executive Officer, as filed), filing under that title since 2026-05-07, 6 months (bottom 8% of its family); the 15 officers and directors filing in the last fifteen months have been on the record a median of 2.3 years (bottom 9%); 12 officer or director changes were reported on Form 8-K since 2023-11-13, against the 15 people in charge now (bottom 20%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Gyre Therapeutics, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $37 million against no long-term debt tagged leaves 22.3% of its assets as net cash, bottom 44% of its family; cash from operations less capital spending is -0.2% of revenue (top 29%); a gross margin of 95.4% (top 8%); research spending of 11.7% of revenue (bottom 16%) (its annual report).

From the record

Gyre Therapeutics, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 4.5% a year over the last three filed years against 80.9% over all 8, slowing (bottom 8% of its family); the newest year grew 10.2% (top 46%); research spending grew -33.2% a year (bottom 11%); capital spending grew -38% a year (bottom 31%) (its annual reports). Gyre Therapeutics, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

From the record

Gyre Therapeutics, Inc.'s newest year against its own record: revenue of $117 million in fiscal 2025 came in 8.4% above the $108 million its prior three years' pace pointed to (top 35% of its family); net income of $10 million against a prior three-year average of $21 million (top 11%); a net margin of 8.5% against -18.1% before (top 42%) (its annual reports).